ReShape Lifesciences Secures NIH Grant for Innovative Diabetes Technology
IRVINE, Calif. — ReShape Lifesciences (NASDAQ: RSLS), a leader in weight loss and metabolic health solutions, recently announced an exciting development. The company has been awarded a $241,000 supplementary grant from the National Institutes of Health (NIH), in collaboration with the University of Southern California’s Center for Autonomic Nerve Recording and Stimulation Systems (CARSS). This funding is geared towards advancing the next-generation electrodes for ReShape’s proprietary Diabetes Bloc-Stim Neuromodulation™ (DBSN™) technology. Aiming to combat Type 2 diabetes, the DBSN™ device uses innovative vagus nerve block (vBloc™) technology alongside vagus nerve stimulation, which directly addresses the challenges associated with obesity and diabetes.
The supplementary grant will facilitate research into minimally invasive techniques for laparoscopic electrode implantation. Furthermore, it will support long-duration experiments focused on safety and blood glucose modulation using a porcine model of diabetes. This research is pivotal for demonstrating the effectiveness of this advanced technology in managing diabetes symptoms.
Understanding the Impact of the DBSN™ Device
The DBSN™ device is designed to intricately regulate nerve signals to critical organs, such as the liver and pancreas, thus resulting in enhanced blood glucose management. Jonathan Waataja, Ph.D., who serves as the Director of Research at ReShape Lifesciences, articulated the significance of this device by stating that it has already shown promising results in regulating blood glucose levels. These results were obtained in studies involving Zucker rats and alloxan-treated swine, bolstered by previous NIH funding.
This latest grant brings the total funding ReShape has received from the NIH to approximately $1.15 million. Paul F. Hickey, the company's President and Chief Executive Officer, notes that this achievement illustrates the robust interest from the NIH in supporting the company’s groundbreaking DBSN™ technology. According to Hickey, the funding will enable the team to test the safety and efficacy of new electrodes, having the potential to significantly increase nerve contact area, which could enhance the effectiveness while conserving power.
ReShape Lifesciences' Commitment to Diabetes Treatment
Furthermore, Hickey emphasizes the company’s dedication to using these funds wisely, having already advanced preclinical development of the DBSN™ device. This device leverages bioelectronics to coordinate insulin production and blood glucose control for individuals battling Type 2 diabetes and related metabolic disorders.
This innovative approach aims not just to provide a treatment option but to considerably reduce the necessity for traditional medications, thereby aiming to lower overall healthcare costs and the complications that arise from poorly maintained blood glucose levels. The technology's effectiveness and potential are underscored by notable preclinical evidence presented at various medical conferences, showcasing the device's promising capabilities.
The Technology Behind the DBSN™ System
The Diabetes Bloc-Stim Neuromodulation™ system embodies a unique therapeutic approach that is implanted using minimally invasive techniques. This innovative system delivers bio-electronic neuromodulation to vagus nerve branches, which are responsible for regulating plasma glucose levels within the body. During the stimulation process, the device prompts the pancreas to release insulin effectively, while simultaneously inhibiting the liver’s glucose release, thereby tackling insulin resistance.
This sophisticated mechanism is a game changer in the realm of personalized medicine. Unlike previous methods of stimulating the vagus nerve that have shown inconsistent results, the DBSN™ system promises a more reliable solution thanks to its reversible and adjustable electrical blockade features.
Final Thoughts on ReShape Lifesciences
ReShape Lifesciences is committed to revolutionizing the obesity treatment landscape. They offer a comprehensive range of proven products and services designed to manage and treat obesity and its associated metabolic diseases. This is exemplified by FDA-approved solutions such as the Lap-Band® system, which provides minimally invasive long-term treatment options as alternatives to more intensive surgical procedures.
The ongoing development of their Diabetes Bloc-Stim Neuromodulation™ system and the innovative Obalon® balloon technology are testaments to ReShape's commitment to driving lasting improvements in metabolic health.
Finally, it is important to note that ReShape has recently entered into an asset purchase agreement with Biorad Medisys, Pvt. Ltd. This agreement involves the sale of substantially all of ReShape's assets. Following the conclusion of this sale, Biorad will assume ownership of the DBSN™ system.
Frequently Asked Questions
What is the main focus of the NIH supplementary grant awarded to ReShape Lifesciences?
The grant was awarded to support the development of next-generation electrodes for the Diabetes Bloc-Stim Neuromodulation™ (DBSN™) device, aimed at effectively managing Type 2 diabetes.
How does the DBSN™ technology work?
The DBSN™ device employs vagus nerve stimulation to help regulate insulin production and manage blood glucose levels, offering a novel approach to diabetes treatment.
What is the purpose of the research being funded by the NIH grant?
The research aims to validate the safety and effectiveness of the new electrodes through minimally invasive techniques and blood glucose modulation studies.
What distinguishes the DBSN™ system from other diabetes treatment options?
The DBSN™ system provides a personalized approach to diabetes treatment, utilizing adjustable electrical blockade technology that enhances treatment outcomes while minimizing reliance on medication.
What other products does ReShape Lifesciences offer?
ReShape provides an integrated suite of products including the Lap-Band® system and Obalon® balloon technology, both designed to aid in the long-term management of obesity and related metabolic issues.
